Shahar Tzafrir

Shahar is a Managing Partner at TLV Partners, investing in the idea/seed stage. Over the past decade, he has focused on the intersection of AI as it addresses commercial problems across sectors, including Biotech, Cloud Native, Construction, Customer Retention, Data Centers, Drug Discovery, Enterprise Software, Health Care, and Taxes.

His investment portfolio at TLV Partners includes Buildots, Bond (exit to Reef), Canopy Immuno-Therapeutics, Covver, Churney, Deepcure, EverAfterAI, Gelt, Granulate (exit to Intel), Guesty (exit via secondary), Immunai, Odo (exit to Checkpoint), Pelanor, Scala Bio-Design, ScyllaDB, Solvo, Silverfort, and Unleash. He also serves as a Board Observer at Aidoc on behalf of the founders.

Before joining TLV Partners, he was a General Partner at Magma Venture Partners, working with funds III and IV. His investment portfolio included Aidoc, Applitools (exit to Thoma Bravo), Cloudendure (exit to Amazon), Coretigo, Guesty (exit via secondary), Indegy (exit to Tenable), ScyllaDB, Syte, Teridion, and Tonkean.

Before his venture capital career, he spent 15 years across three startups: Federation (acquired by Cordys), Oblicore (acquired by CA), and DigitalFuel (acquired by VMWare).

He served in Israel’s Defense Forces for six years in his early career, earning three annual distinction awards at the Unit, Division, and Corps levels.

He earned his LLB, graduating Summa Cum Laude and as the class Valedictorian. He consistently ranked #1 on the dean’s list each year. Outside of work, he is an amateur nature photographer and a chess player interested in Advanced Chess, a blend of AI and human strategy.